Exportin-1: a new targeting anticancer drugs
A recent study found that cancer cells mayu clarify the mechanism of action of new cancer drugs. In human cells, the nucleus containing our DNA, and as a "control center", and acts as the cell's cytoplasm "body." It is here that the protein can be generated and recycled. However, if there is an active or inactive protein is dependent on its position in the cell. Cell transport system used to ensure that the protein needs to reach its site. In healthy cells, the protein is constantly being conveyed between the nucleus and cytoplasm.
With the assistance of transport proteins and transport out of the nucleus. Exportin-1 transport more than 200 kinds of different proteins. Exportin-1 is a tumor suppressor protein. When in the nucleus, these proteins are able to detect damaged DNA, and triggers cell death. However, some cancer cells through the delivery of anti-cancer proteins into the cytoplasm and the nucleus, disrupting the normal operation of Exportin-1, where the work they perform suppress cancer is prevented.
Rega Institute and Department of Chemistry researchers previously reported inhibitor Exportin-1's. Karyopharm Therapeutics company focused on the discovery and development of new nuclear transport targets for drugs, have been identified and developed Exportin-1 inhibitor KPT-330 for the treatment of cancer. In the new study, the researchers confirmed that KPT-330 capable of targeting and blocking Exportin-1. Molecular KPT-330 can be connected to a particular amino acid (building block Exportin-1 protein).